HS
BBIO icon

HighVista Strategies’s BridgeBio Pharma BBIO Stock Holding History

HighVista Strategies’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$980K Sell
13,156
-36,404
-73% -$2.55M 0.22% 120
2026
Q1 		$3.68M Sell
49,560
-30,645
-38% -$2.22M 1.02% 25
2025
Q4 		$6.13M Sell
80,205
-1,754
-2% -$115K 1.58% 17
2025
Q3 		$4.26M Buy
81,959
+14,460
+21% +$705K 1.04% 23
2025
Q2 		$2.91M Buy
67,499
+20,999
+45% +$764K 1.07% 19
2025
Q1 		$1.61M Hold
46,500
– – 0.62% 60
2024
Q4 		$1.28M Sell
46,500
-22,554
-33% -$583K 0.47% 94
2024
Q3 		$1.76M Buy
69,054
+24,482
+55% +$643K 0.61% 62
2024
Q2 		$1.13M Sell
44,572
-11,990
-21% -$328K 0.41% 98
2024
Q1 		$1.75M Buy
56,562
+11,990
+27% +$408K 0.62% 55
2023
Q4 		$1.8M Hold
44,572
– – 0.65% 51
2023
Q3 		$1.18M Buy
+44,572
New +$1.26M 0.54% 51
2022
Q3 		– Sell
-105,942
Closed -$962K – 115
2022
Q2 		$962K Buy
105,942
+20,642
+24% +$173K 0.58% 39
2022
Q1 		$866K Buy
85,300
+51,450
+152% +$528K 0.55% 51
2021
Q4 		$565K Buy
33,850
+9,198
+37% +$389K 0.45% 63
2021
Q3 		$1.16M Buy
24,652
+11,596
+89% +$622K 0.76% 41
2021
Q2 		$796K Buy
+13,056
New +$746K 0.56% 50

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

HighVista Strategies's BBIO Position: Q2 2026 in Review

HighVista Strategies reduced its BridgeBio Pharma (BBIO) stake by 73% in Q2 2026, selling an estimated $2.55M and leaving 13,156 shares worth $980K. The position accounts for 0.22% of the portfolio, ranked #120.

HighVista Strategies first reported a position in BBIO in Q2 2021 and has held it in 17 quarters since. The position peaked at $6.13M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • HighVista Strategies held 13,156 shares of BridgeBio Pharma worth $980K as of Q2 2026.
  • HighVista Strategies sold 36,404 BridgeBio Pharma shares in Q2 2026, an estimated $2.55M.
  • BridgeBio Pharma made up 0.22% of HighVista Strategies's portfolio in Q2 2026, its #120 holding.
  • HighVista Strategies first reported a position in BridgeBio Pharma in Q2 2021 and has held it in 17 quarters since.
  • HighVista Strategies's BridgeBio Pharma position peaked at $6.13M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.